Investment Analysts’ Weekly Ratings Changes for Sucampo Pharmaceuticals (SCMP)

Several brokerages have updated their recommendations and price targets on shares of Sucampo Pharmaceuticals (NASDAQ: SCMP) in the last few weeks:

  • 2/9/2018 – Sucampo Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Sucampo’s pending acquisition by Mallinckrodt for $1.2 billion have raised investor concerns that the latter may be underpaying for the company. A sNDA for label expansion of Amitizia in pediatric functional constipation is under review. Also, Sucampo’s collaborations with firms like Takeda and Mylan for Amitiza’s commercialization is a big positive. Moreover, the Vtesse acquisition added a pivotal program in Niemann-Pick Disease type C1 to its pipeline. However, Sucampo’s dependence on Amitiza for growth is concerning with few companies trying to market and sell generic version of Amitiza. Moreover, Sucampo discontinued Amitzia’s sprinkle formulation development as it did not meet bioequivalence with capsule formulation. Shares of the company have outperformed the industry. Estimates have remained stable ahead of the Q4 earnings results. The company has a mixed record of earnings surprises in recent quarters.”
  • 2/2/2018 – Sucampo Pharmaceuticals was upgraded by analysts at ValuEngine from a “buy” rating to a “strong-buy” rating.
  • 2/1/2018 – Sucampo Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $20.00 price target on the stock. According to Zacks, “Sucampo’s pending acquisition by Mallinckrodt for $1.2 billion have raised investor concerns that the latter may be underpaying for the company. A sNDA for label expansion of Amitizia in pediatric functional constipation is under review. Also, Sucampo’s collaborations with firms like Takeda and Mylan for Amitiza’s commercialization is a big positive. Moreover, the Vtesse acquisition added a pivotal program in Niemann-Pick Disease type C1 to its pipeline. However, Sucampo’s dependence on Amitiza for growth is concerning with few companies trying to market and sell generic version of Amitiza. Moreover, Sucampo discontinued Amitzia’s sprinkle formulation development as it did not meet bioequivalence with capsule formulation. Shares of the company have outperformed the industry. Estimates have remained stable ahead of the Q4 earnings results. The company has a mixed record of earnings surprises in recent quarters.”
  • 1/31/2018 – Sucampo Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Sucampo’s pending acquisition by Mallinckrodt for $1.2 billion have raised investor concerns that the latter may be underpaying for the company. A sNDA for label expansion of Amitizia in pediatric functional constipation is under review. Also, Sucampo’s collaborations with firms like Takeda and Mylan for Amitiza’s commercialization is a big positive. Moreover, the Vtesse acquisition added a pivotal program in Niemann-Pick Disease type C1 to its pipeline. However, Sucampo’s dependence on Amitiza for growth is concerning with few companies trying to market and sell generic version of Amitiza. Moreover, Sucampo discontinued Amitzia’s sprinkle formulation development as it did not meet bioequivalence with capsule formulation. Shares of the company have outperformed the industry. Estimates have remained stable ahead of the Q4 earnings results. The company has a mixed record of earnings surprises in recent quarters.”
  • 1/26/2018 – Sucampo Pharmaceuticals had its “neutral” rating reaffirmed by analysts at Nomura. They now have a $18.00 price target on the stock.
  • 1/5/2018 – Sucampo Pharmaceuticals was downgraded by analysts at UBS Group AG from a “buy” rating to a “neutral” rating. They now have a $18.00 price target on the stock.
  • 1/3/2018 – Sucampo Pharmaceuticals had its “neutral” rating reaffirmed by analysts at Mizuho. They now have a $18.00 price target on the stock, up previously from $14.00.
  • 1/2/2018 – Sucampo Pharmaceuticals had its “market perform” rating reaffirmed by analysts at Leerink Swann. They now have a $15.00 price target on the stock.
  • 1/1/2018 – Sucampo Pharmaceuticals was downgraded by analysts at Maxim Group to a “hold” rating.
  • 12/31/2017 – Sucampo Pharmaceuticals was upgraded by analysts at ValuEngine from a “buy” rating to a “strong-buy” rating.
  • 12/26/2017 – Sucampo Pharmaceuticals was downgraded by analysts at B. Riley from a “buy” rating to a “neutral” rating. They now have a $18.00 price target on the stock.
  • 12/26/2017 – Sucampo Pharmaceuticals was downgraded by analysts at Maxim Group from a “buy” rating to a “hold” rating.
  • 12/19/2017 – Sucampo Pharmaceuticals is now covered by analysts at Instinet. They set a “buy” rating and a $43.00 price target on the stock.
  • 12/18/2017 – Sucampo Pharmaceuticals is now covered by analysts at Nomura. They set a “buy” rating and a $43.00 price target on the stock.

Shares of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) remained flat at $$18.00 during trading on Tuesday. 956,100 shares of the company’s stock were exchanged, compared to its average volume of 2,557,332. The company has a debt-to-equity ratio of 7.37, a quick ratio of 4.46 and a current ratio of 5.11. The stock has a market cap of $849.02, a P/E ratio of -5.47, a P/E/G ratio of 5.06 and a beta of 1.38. Sucampo Pharmaceuticals, Inc. has a fifty-two week low of $9.30 and a fifty-two week high of $18.75.

In other Sucampo Pharmaceuticals news, insider Peter A. Kiener sold 50,000 shares of Sucampo Pharmaceuticals stock in a transaction on Thursday, December 7th. The stock was sold at an average price of $16.50, for a total transaction of $825,000.00. Following the sale, the insider now owns 52,023 shares of the company’s stock, valued at approximately $858,379.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.13% of the stock is owned by insiders.

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Receive News & Ratings for Sucampo Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply